Approval · Notice of Compliance 38041 · 2026
ULTOMIRIS: Notice of Compliance 38041
Issued August 5, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38041
- Date
- August 5, 2026
- Company
- Alexion Pharma GmbhBaar, --, Switzerland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ULTOMIRIS | Not yet assigned | — |
Medicinal ingredients
- RAVULIZUMAB 300 MG per 3ML
- RAVULIZUMAB 1,100 MG per 11ML